HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radioactive cancer drug trial halted early
Disease control TerminatedThis study tested a radioactive drug called [225Ac]-FPI-1434 in people with advanced solid tumours that had not responded to standard treatments. The goal was to find a safe dose and see if it could shrink tumours. The trial was stopped early, so results are limited. Participants…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested an experimental drug called TransCon TLR7/8 Agonist, alone or with another drug (pembrolizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The trial was t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated May 26, 2026 03:06 UTC